Skip to main content
. 2022 Jun 28;13:901030. doi: 10.3389/fimmu.2022.901030

Figure 2.

Figure 2

JunB promotes accumulation of antigen-primed CD4+ T cells in vivo. Naive Junbfl/fl OT-II or Junbfl/flCd4Cre OT-II cells (CD45.2+) were co-transferred with congenic wild-type OT-II cells (CD45.1+CD45.2+) at a 2:1 ratio into congenic recipient mice (CD45.1+). One day later, mice were immunized with OVA323-339 peptides emulsified in CFA or mixed with LPS or papain. At 5 dpi, cells were isolated from draining lymph nodes and analyzed by flow cytometry. (A) Immunization scheme. i.v. intravenous injection, s.c. subcutaneous injection, i.n. intranasal injection. (B–D) Flow cytometry analysis of CD45.1 and CD45.2 expression in CD3+CD4+ T cells isolated from mice immunized with CFA (B), LPS (C), and papain (D). Bar graphs show the ratio of Junbfl/fl OT-II or Junbfl/flCd4Cre OT-II cells (CD45.2+) vs co-transferred OT-II cells (CD45.1+CD45.2+). (E–G) Flow cytometry analysis of IL-17A and IFN-γ expression (E, F) and IL-4 and IL-13 expression (G) in OT-II cells (CD3+CD4+CD45.2+) isolated from mice immunized with CFA (E), LPS (F), and papain (G). Bar graphs indicate the percentage of cells expressing the indicated cytokines in Junbfl/fl OT-II or Junbfl/flCd4Cre OT-II cells. (B–F) Error bars indicate s.d. (n = 4-6 mice per group). **p < 0.01, ***p < 0.001, ****p < 0.0001, (unpaired two-tailed Student’s t-test). Data represent two independent experiments.